1stOncology™: Cancer Intelligence Service – Page 14766 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls

On July 9, 2019 Exact Sciences Corp. (Nasdaq: EXAS) reported that the company will host webcasts and conference calls of its annual stockholders meeting and its second-quarter 2019 financial results (Press release, Exact Sciences, JUL 9, 2019, View Source [SID1234537429]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Annual Meeting of Stockholders Webcast & Conference Call Details

Date:

Thursday, July 25, 2019

Time:

11 a.m. ET, 10 a.m. CT

Webcast:

The live webcast can be accessed at www.exactsciences.com

Telephone:

Domestic callers, dial 877-201-0168

International callers, dial +1 647-788-4901

Access code for both domestic and international callers: 2171853

Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP)
The company plans to release its second-quarter 2019 financial results after the close of the U.S. financial markets on July 30, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Second-Quarter 2019 Webcast & Conference Call Details

Date:

Tuesday, July 30, 2019

Time:

5 p.m. ET, 4 p.m. CT

Webcast:

The live webcast can be accessed at www.exactsciences.com

Telephone:

Domestic callers, dial 877-201-0168

International callers, dial +1 647-788-4901

Access code for both domestic and international callers: 8288326

An archive of the webcast will be available at www.exactsciences.com. A replay of the annual meeting and second-quarter conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally. The annual meeting replay can be accessed with the code 2171853. The access code for the second-quarter replay is 8288326. The webcast, conference call and replays are open to all interested parties.

CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration

On July 9, 2019 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates ("PDC") (Press release, CytomX Therapeutics, JUL 9, 2019, View Source [SID1234537428]). The target selection triggers a $10 million payment to CytomX from AbbVie. This is the second of two research targets available to AbbVie under the agreement. The companies are also advancing a clinical-stage asset, CX-2029, under a global co-development and licensing agreement.

"The initiation of this additional program with AbbVie and the associated milestone payment reflects the growing strength of clinical proof of concept CytomX has achieved in support of the Probody platform. It also further underscores the potential of our unique technology to make meaningful differences for cancer patients. We are excited to start this new program with our AbbVie colleagues," said Sean McCarthy D.Phil., president, chief executive officer and chairman of CytomX Therapeutics.

About the Discovery Collaboration and Licensing Agreement

Under the terms of the April 2016 Discovery Collaboration and Licensing Agreement, AbbVie receives exclusive worldwide rights to develop and commercialize PDCs against up to two targets, which were selected in March 2017 and June 2019. In each case, CytomX is responsible for certain research and pre-clinical activities with AbbVie leading pre-clinical and clinical development and commercialization of products arising from the collaboration. CytomX received an upfront payment of $10 million for each target selection and is eligible to receive up to $275 million in development, regulatory and commercial milestone payments and royalties in the high single to low teens from commercial sales of any resulting PDCs.

About the CX-2029 Co-Development and Licensing Agreement

Pursuant to the April 2016 Co-Development and Licensing Agreement, CytomX and AbbVie are also co-developing CX-2029, a PDC against CD71. CD71, also known as transferrin receptor 1 ("TfR1"), is a cell surface protein that is essential for iron uptake in dividing cells, is highly expressed in a number of solid and hematologic cancers and has attractive molecular properties for efficient delivery of cytotoxic payloads to tumor cells. CytomX received an upfront payment of $20 million, is eligible to receive up to $470 million in development, regulatory and commercial milestone payments, pending the achievement of pre-determined outcomes. CytomX is responsible for research activities and leading early-stage clinical development of CX-2029. AbbVie will lead global commercial activities with CytomX eligible to receive a profit share in the U.S. and tiered double-digit royalties on net product sales outside of the U.S. CytomX retains an option to co-promote in the U.S. CytomX initiated PROCLAIM-CX-2029, a Phase 1 dose escalation trial, in June 2018.

BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline

On July 9, 2019 BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, reported the completion of a USD 325 million Series B financing round, making it one of the largest single private funding rounds for a biotechnology company in European history (Press release, BioNTech, JUL 9, 2019, View Source [SID1234537427]). The fund raising was upsized and was led by Fidelity Management & Research Company with participation from both new and existing investors, including Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Struengmann Family Office. Two-thirds of the funding came from new investors. The proceeds of the financing will support the continued advancement of BioNTech’s therapeutics pipeline and manufacturing infrastructure.

"BioNTech has executed on a highly disruptive business strategy that aims to change the treatment paradigm for cancer patients," said Helmut Jeggle, Chairman of BioNTech. "We value the continued participation of our existing investors and welcome new investors to this powerful global syndicate representing North America, Asia and Europe."

Prof. Ugur Sahin, CEO and Co-Founder of BioNTech added: "This financing round is a significant milestone that recognizes our scientific and initial clinical track record to date. With our ongoing focus on bringing together transformative technologies, it is exciting to have the support from high-technology investors who see the accelerating convergence of biology with bioinformatics, robotics and artificial intelligence as an opportunity to develop more precise, efficacious and cost-effective individualized immunotherapies."

The funding follows the Series A financing of USD 270 million announced in January 2018, led by Redmile Group. The previous financings have enabled BioNTech to advance a pipeline of seven product candidates in eight ongoing clinical trials, to establish a second GMP manufacturing license for production of its individualized neoantigen specific immunotherapies and to expand its antibody platform, most recently, through the acquisition of a Phase I/IIa program against pancreatic cancer from MabVax Therapeutics Inc. In conjunction with the MabVax Therapeutics acquisition of assets, the company has also recently established its US research and development facility in San Diego, California.

Immatics Appoints Harpreet Singh as Chief Executive Officer

On July 8, 2019 Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, reported that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO) (Press release, Immatics Biotechnologies, JUL 8, 2019, View Source [SID1234569544]).

Harpreet Singh has most recently been President and CEO of Immatics US and Chief Scientific Officer (CSO) of the Company, having co-founded Immatics. He has been instrumental in growing the Company from a start-up to a leading player in the field of immuno-oncology.

Peter Chambré, Chairman of Immatics, says: "The Board is delighted to appoint Harpreet as CEO to lead Immatics in the next phase of its development, as the Company progresses its pipeline of immunotherapy candidates. Harpreet is an exceptional organizational leader and scientist and over the past three years has led the building of the Immatics US organization and creation of Immatics’ clinical pipeline and capabilities in adoptive cellular therapy, as well as guiding the Company’s overall scientific development since its early days. We are very excited about the prospects and opportunities for Immatics, with Harpreet as CEO."

Harpreet Singh comments: "I am thrilled to be chosen as CEO of Immatics. We hold the key to unlock the power of cancer immunotherapies in solid cancers. Built on world-leading target and TCR discovery platforms we are developing powerful pipelines of novel adoptive cellular as well as bispecific therapy products – on our own, as well as with world-class partners. The opportunity to lead this exceptional company and its outstanding people that are passionately dedicated to delivering the power of T cells to cancer patients, is a true privilege."

IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline

On July 8, 2019 IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of engineered IgM antibodies for therapeutic use, reported the closing of its $102 million Series C financing. New investors included Redmile Group, Janus Henderson Investors, Vivo Capital and another large U.S.-based, healthcare-focused fund. Haldor Topsøe Holding A/S, which has funded IGM since 2010, also participated in the round (Press release, IGM Biosciences, JUL 8, 2019, View Source [SID1234538902]).

"We are very pleased to have the support of these sophisticated healthcare-focused investors," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "We look forward to working with them to realize the potential of our IgM platform to deliver new therapeutic treatments to patients with cancer."

Proceeds from this financing will be used to advance the Company’s IgM platform technology and its proprietary oncology pipeline, including its lead program, a CD20 x CD3 bispecific antibody, which is expected to enter the clinic later this year.